Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2014-09-11 05:14:37 UTC |
---|
Update Date | 2014-12-24 20:26:56 UTC |
---|
Accession Number | T3D4747 |
---|
Identification |
---|
Common Name | Cyproterone acetate |
---|
Class | Small Molecule |
---|
Description | An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. |
---|
Compound Type | - Drug
- Ester
- Ether
- Organic Compound
- Organochloride
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | Androcur | Cyprostat | Cyproterone 17-O-acetate | Cyproterone acetic acid |
|
---|
Chemical Formula | C24H29ClO4 |
---|
Average Molecular Mass | 416.938 g/mol |
---|
Monoisotopic Mass | 416.175 g/mol |
---|
CAS Registry Number | 427-51-0 |
---|
IUPAC Name | (1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo[9.7.0.0²,⁸.0³,⁵.0¹²,¹⁶]octadeca-7,9-dien-15-yl acetate |
---|
Traditional Name | cyproterone acetate |
---|
SMILES | [H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H] |
---|
InChI Identifier | InChI=1/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/s2 |
---|
InChI Key | InChIKey=UWFYSQMTEOIJJG-HEULQOMWNA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Pregnane steroids |
---|
Direct Parent | Gluco/mineralocorticoids, progestogins and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Progestogin-skeleton
- 20-oxosteroid
- Steroid ester
- 3-oxosteroid
- 6-halo-steroid
- Halo-steroid
- Oxosteroid
- Cyclohexenone
- Alpha-acyloxy ketone
- Ketone
- Carboxylic acid ester
- Haloalkene
- Chloroalkene
- Monocarboxylic acid or derivatives
- Carboxylic acid derivative
- Vinyl chloride
- Vinyl halide
- Organooxygen compound
- Organochloride
- Organohalogen compound
- Hydrocarbon derivative
- Organic oxygen compound
- Organic oxide
- Carbonyl group
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 200-201°C | Boiling Point | Not Available | Solubility | Not Available | LogP | Not Available |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-0006-9211100001-d28e5fdc8591481f22f9 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-01t9-3971000000-1dfca0904cf6f0055e70 | 2017-09-14 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-014i-0009600000-b58e59a860b40f6fa16a | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-05r1-1079100000-2b2076ee4e989b996df7 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-000m-6090000000-a52f873929348166d62a | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-01b9-2007900000-9919c0052c65d1218b0b | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-05fr-2009100000-dd4f568fa03074230f01 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0a4i-7019000000-5bd7b03633e9ae6146ac | 2016-08-03 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 50.18 MHz, CDCl3, experimental) | Not Available | 2014-09-23 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Completely absorbed following oral administration. |
---|
Mechanism of Toxicity | The direct antiandrogenic effect of cyproterone is blockage of the binding of dihydrotestosterone to the specific receptors in the prostatic carcinoma cell. In addition, cyproterone exerts a negative feed-back on the hypothalamo-pituitary axis, by inhibiting the secretion of luteinizing hormone resulting in diminished production of testicular testosterone. |
---|
Metabolism | Primarily hepatic. Cyproterone acetate is metabolized by the CYP3A4 enzyme, forming the active metabolite 15beta-hydroxycyproterone acetate, which retains its antiandrogen activity, but has reduced progestational activity.
Route of Elimination: It is excreted approximately 60% in the bile and 33% through the kidneys.
Half Life: Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively. |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | For the palliative treatment of patients with advanced prostatic carcinoma. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Not Available |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB04839 |
---|
HMDB ID | Not Available |
---|
PubChem Compound ID | Not Available |
---|
ChEMBL ID | CHEMBL142130 |
---|
ChemSpider ID | Not Available |
---|
KEGG ID | Not Available |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 50743 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Not Available |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Cyproterone_acetate |
---|
References |
---|
Synthesis Reference | Aranya Manosroi, “Synthesis of cyproterone acetate.” U.S. Patent US20040024230, issued February 05, 2004. |
---|
MSDS | Not Available |
---|
General References | - Giorgi EP, Shirley IM, Grant JK, Stewart JC: Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate. Biochem J. 1973 Mar;132(3):465-74. [4125095 ]
- Pham-Huu-Trung MT, de Smitter N, Bogyo A, Girard F: Effects of cyproterone acetate on adrenal steroidogenesis in vitro. Horm Res. 1984;20(2):108-15. [6237971 ]
- Stadtler FA, Langner V: The effect of cyproterone and gonadotrophins on the adrenal gland of juvenile and adult rats. A morphological and morphometrical study. Pathol Res Pract. 1985 Mar;179(4-5):493-8. [4001026 ]
- Honer C, Nam K, Fink C, Marshall P, Ksander G, Chatelain RE, Cornell W, Steele R, Schweitzer R, Schumacher C: Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol Pharmacol. 2003 May;63(5):1012-20. [12695529 ]
- Holdaway IM, Croxson MS, Evans MC, France J, Sheehan A, Wilson T, Ibbertson HK: Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism. Acta Endocrinol (Copenh). 1983 Oct;104(2):222-6. [6227191 ]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|